Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS
This study provides Class III evidence that HBV during initiation of anti-CD20 therapy is less effective in establishing seroprotection to hepatitis B than in patients in whom HBV is completed before initiation of anti-CD20 therapy.
Authors
- Ariadna Rando‐Segura (ORCID: https://orcid.org/0000-0003-4555-7286)
- Juliana Esperalba (ORCID: https://orcid.org/0000-0003-1326-1341)
- Carmen Tur (ORCID: https://orcid.org/0000-0003-1849-3184)
- Ricardo Zules-Oña (ORCID: https://orcid.org/0000-0002-3648-4321)
- Álvaro Cobo‐Calvo (ORCID: https://orcid.org/0000-0002-2574-0721)
- René Carvajal (ORCID: https://orcid.org/0000-0003-3583-8412)
- Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
- Xavier Martínez‐Gómez (ORCID: https://orcid.org/0000-0003-4583-9734)
- Mar Tintoré (ORCID: https://orcid.org/0000-0001-9999-5359)
- Pere Carbonell‐Mirabent (ORCID: https://orcid.org/0000-0003-1349-9261)
- Susana Otero‐Romero (ORCID: https://orcid.org/0000-0002-6798-568X)
- José Ángel Rodrigo‐Pendás (ORCID: https://orcid.org/0000-0002-2383-9904)
- Marta Rodríguez‐Barranco (ORCID: https://orcid.org/0000-0001-5454-3041)
- Blanca Borràs-Bermejo (ORCID: https://orcid.org/0000-0003-4111-5632)
- David Guananga-Álvarez (ORCID: https://orcid.org/0009-0009-0791-3906)
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
Publication Details
- Journal
- Neurology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1212/wnl.0000000000210281
- Citations
- 4
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- National Multiple Sclerosis Society
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- European Committee for Treatment and Research in Multiple Sclerosis
- TG Therapeutics
- Mylan
- European Commission
- Ministerio de Ciencia e Innovación
- Fondation Charcot
- Multiple Sclerosis International Federation
- MedDay Pharmaceuticals
- EMD Serono
- Sanofi Pasteur
- Instituto de Salud Carlos III
- Statens Serum Institut
- Janssen Pharmaceuticals